Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals is a clinical-stage and commercial therapeutics company focused on developing and commercializing clinician-administered medications for dermatologic diseases and skin cancers. Its primary commercial product is YCANTH, an FDA-approved topical formulation of cantharidin delivered via a single-use precision applicator for treating molluscum contagiosum. The company's development pipeline includes advancing YCANTH for the treatment of common warts, as well as developing VP-315, an investigational injectable peptide therapy for dermatological oncology conditions such as basal cell carcinoma. Its offerings primarily target pediatric dermatologists, general dermatologists, pediatricians, and other primary care health care providers.

The company operates primarily in the United States, where it employs a specialized sales organization of approximately 40 field sales representatives and contractors, and reaches approximately 250 million covered lives through insurance coverage determinations. Internationally, the company licenses commercial and development rights in Japan to Torii Pharmaceutical Co., Ltd. The provided text does not state the location of the company's headquarters.

Summary of the business section of Verrica Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 76 full-time employees.”